ロード中...
Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis
BACKGROUND: In a randomised phase III trial, sunitinib significantly improved efficacy over interferon-α (IFN-α) as first-line therapy for metastatic renal cell carcinoma (mRCC). We report the final health-related quality of life (HRQoL) results. METHODS: Patients (n=750) received oral sunitinib 50 ...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group
2010
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2837567/ https://ncbi.nlm.nih.gov/pubmed/20104222 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605552 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|